PT - JOURNAL ARTICLE AU - Veyrenche, N AU - Pisoni, A AU - Debiesse, S AU - Bollore, K AU - Bedin, AS AU - Makinson, A AU - Niel, C AU - Alcocer-Cordellat, C AU - Mondain, AM AU - Le Moing, V AU - Van de Perre, P AU - Tuaillon, E TI - SARS-CoV-2 nucleocapsid antigen in urine of hospitalized patients with Covid-19 AID - 10.1101/2021.09.28.21264239 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.28.21264239 4099 - http://medrxiv.org/content/early/2021/10/01/2021.09.28.21264239.short 4100 - http://medrxiv.org/content/early/2021/10/01/2021.09.28.21264239.full AB - Introduction SARS-CoV-2 nucleocapsid antigen (N-Ag) can be detected in the blood of patients with Covid-19. In this study, we used a highly sensitive and specific nucleocapsid-Ag assay to explore the presence of N-Ag in urine during the course of Covid-19, and explore its relationship with the severity of the disease.Material and Methods Urine and blood samples were collected from 82 patients with a SARS-CoV-2 infection proven by PCR and included in the COVIDotheque. We explored the presence of N-Ag in urine and blood using the AAZ N-Ag test, studied the kinetics of the marker according to the time since the onset of symptoms and evaluated the association between N-Ag levels, clinical severity and inflammation.Results In the first and second weeks of Covid-19, hospitalized patients tested positive for urinary N-Ag (81.25% and 71.79%, respectively) and blood N-Ag (93.75% and 94.87%, respectively). N-Ag levels in urine and blood were moderately correlated with the number of days after the onset of symptoms (r=-0.43, p<0.0001; r=-0.55 p<0.0001, respectively). The follow up of seven SARS-CoV-2 infected patients confirmed the waning of N-Ag in urine and blood over the course of the disease. High urinary N-Ag levels were associated with the absence of SARS-CoV-2 nucleocapsid-IgG (N-IgG), admission in intensive care units, high C-reactive protein levels, lymphopenia, eosinopenia, and high lactate dehydrogenase (LDH).Conclusion Our study demonstrate that N-Ag is present in the urine of patients hospitalized in the early phase of Covid-19. As a direct marker of SARS-CoV-2, urinary N-Ag reflects the dissemination of viral compounds in the body. Urine N-Ag is a promising marker to predict adverse evolution of SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04347850Funding StatementThis work was funded by the Montpellier University Hospital, Muse I‐SITE Program Grant, University of Montpellier.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The cohort study received an institutional ethics committee approval (CPP Ile de France III, number 2020‐A00935−34; ClinicalTrials. gov Identifier: NCT04347850).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study are available from the corresponding author on reasonable request.